All In Biotech

Drug Trial Radar · NCT06989359

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Aug 28, 2025

Primary completion

Apr 30, 2030

Study completion Jul 31, 2030

Sponsor

Lead sponsor
ADARx Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Conditions

  • IgAN
  • C3G
  • Complement-mediated Kidney Disease
  • IgA Nephropathy (IgAN)
  • IC-MPGN

Interventions

  • ADX-038 Dose Level 2Drug

    siRNA duplex oligonucleotide

  • ADX-038 Dose Level 1Drug

    siRNA duplex oligonucleotide

  • ADX-038 Dose Level 3Drug

    siRNA duplex oligonucleotide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of ADX-038Time frame: Length of study - From Day 1 through Month 24

Locations

38 sites in 8 countries. Site status is shown where the registry gives one.

  • ADARx Clinical Site

    Doral, Florida · Withdrawn

  • ADARx Clinical Site

    Miami, Florida · Recruiting

  • ADARx Clinical Site

    Pembroke Pines, Florida · Withdrawn

  • ADARx Clinical Site

    Iowa City, Iowa · Recruiting

  • ADARx Clinical Site

    Shreveport, Louisiana · Withdrawn

  • ADARx Clinical Site

    Shelby, Michigan · Recruiting

  • ADARx Clinical Site

    Great Neck, New York · Recruiting

  • ADARx Clinical Site

    Columbus, Ohio · Recruiting

  • ADARx Clinical Site

    Dakota Dunes, South Dakota · Recruiting

  • ADARx Clinical Site

    Dallas, Texas · Withdrawn

  • ADARx Clinical Site

    Houston, Texas · Recruiting

  • ADARx Clinical Site

    Sydney, Australia · Recruiting

  • ADARx Clinical Site

    Woolloongabba, Australia · Recruiting

  • ADARx Clinical Site

    Liverpool, New South Wales, Australia · Recruiting

  • ADARx Clinical Site

    Wollongong, New South Wales, Australia · Recruiting

  • ADARx Clinical Site

    Hong Kong, Hong Kong · Recruiting

  • ADARx Clinical Site

    Shatin, Hong Kong · Recruiting

  • ADARx Clinical Site

    Bergamo, Italy · Recruiting

  • ADARx Clinical Site

    Bologna, Italy · Recruiting

  • ADARx Clinical Site

    Pavia, Italy · Recruiting

  • ADARx Clinical Site

    Cheonan, South Korea · Recruiting

  • ADARx Clinical Site

    Daegu, South Korea · Recruiting

  • ADARx Clinical Site

    Gyeonggi-do, South Korea · Recruiting

  • ADARx Clinical Site

    Seoul, South Korea · Recruiting

  • ADARx Clinical Site

    Seoul, South Korea · Recruiting

  • ADARx Clinical Site

    Seoul, South Korea · Recruiting

  • ADARx Clinical Site

    Seoul, South Korea · Recruiting

  • ADARx Clinical Site

    Wŏnju, Gangwon-do, South Korea · Recruiting

  • ADARx Clinical Site

    Gyeonggi-do, Gurogu, South Korea · Recruiting

  • ADARx Clinical Site

    Seoul, Gurogu, South Korea · Recruiting

  • ADARx Clinical Site

    Barcelona, Spain · Recruiting

  • ADARx Clinical Site

    Madrid, Spain · Recruiting

  • ADARx Clinical Site

    Madrid, Spain · Recruiting

  • ADARx Clinical Site

    Seville, Spain · Recruiting

  • ADARx Clinical Site

    Kaohsiung City, Taiwan · Not yet recruiting

  • ADARx Clinical Site

    New Taipei City, Taiwan · Recruiting

  • ADARx Clinical Site

    Newcastle upon Tyne, United Kingdom · Recruiting

  • ADARx Clinical Site

    Leicester, BC, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.